Harrow Inc (HROW)
17.87
-0.69
(-3.72%)
USD |
NASDAQ |
May 29, 16:00
17.87
0.00 (0.00%)
After-Hours: 20:00
Harrow Enterprise Value: 764.51M for May 28, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 28, 2024 | 764.51M |
May 24, 2024 | 740.80M |
May 23, 2024 | 727.01M |
May 22, 2024 | 717.10M |
May 21, 2024 | 691.27M |
May 20, 2024 | 701.88M |
May 17, 2024 | 700.82M |
May 16, 2024 | 679.59M |
May 15, 2024 | 671.28M |
May 14, 2024 | 682.42M |
May 13, 2024 | 534.88M |
May 10, 2024 | 518.25M |
May 09, 2024 | 471.90M |
May 08, 2024 | 472.96M |
May 07, 2024 | 494.90M |
May 06, 2024 | 478.98M |
May 03, 2024 | 475.08M |
May 02, 2024 | 484.28M |
May 01, 2024 | 476.85M |
April 30, 2024 | 468.36M |
April 29, 2024 | 483.57M |
April 26, 2024 | 480.39M |
April 25, 2024 | 461.64M |
April 24, 2024 | 471.19M |
April 23, 2024 | 472.96M |
Date | Value |
---|---|
April 22, 2024 | 482.87M |
April 19, 2024 | 477.56M |
April 18, 2024 | 491.71M |
April 17, 2024 | 526.03M |
April 16, 2024 | 543.02M |
April 15, 2024 | 544.78M |
April 12, 2024 | 555.39M |
April 11, 2024 | 574.50M |
April 10, 2024 | 565.30M |
April 09, 2024 | 575.20M |
April 08, 2024 | 575.20M |
April 05, 2024 | 585.82M |
April 04, 2024 | 573.08M |
April 03, 2024 | 571.31M |
April 02, 2024 | 545.84M |
April 01, 2024 | 560.70M |
March 31, 2024 | 575.91M |
March 28, 2024 | 567.90M |
March 27, 2024 | 550.22M |
March 26, 2024 | 544.91M |
March 25, 2024 | 524.40M |
March 22, 2024 | 506.72M |
March 21, 2024 | 474.19M |
March 20, 2024 | 472.07M |
March 19, 2024 | 476.66M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
73.09M
Minimum
Mar 23 2020
987.44M
Maximum
May 09 2023
309.71M
Average
224.28M
Median
Mar 04 2022
Enterprise Value Benchmarks
Durect Corp | 31.66M |
Aquestive Therapeutics Inc | 215.80M |
Cyclacel Pharmaceuticals Inc | 0.1432M |
Stereotaxis Inc | 145.68M |
Cara Therapeutics Inc | -33.40M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -13.56M |
Revenue (Quarterly) | 34.59M |
Total Expenses (Quarterly) | 41.52M |
EPS Diluted (Quarterly) | -0.38 |
Gross Profit Margin (Quarterly) | 69.49% |
Profit Margin (Quarterly) | -39.22% |
Earnings Yield | -5.15% |
Normalized Earnings Yield | -5.000 |